

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936  
 Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936

Novartis Pharmaceuticals Corporation<sup>1),2)</sup>

Novartis Pharmaceuticals Corporation 70-90%<sup>3),4),5),6),7)</sup>

References

- 1) J.M.J. Alvir, J.A. Lieberman, A.Z. Safferman, J.L. Schwimmer, J.A. Schaaf: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. *N Engl J Med*, 329, 162-167, 1993.
- 2) J. Munro, D. O’Sullivan, C. Andrews, A. Arana, A. Mortimer, R. Kerwin: Active monitoring of 12760 clozapine recipients in the UK and Ireland. *Br J Psychiatry*, 175, 576-580, 1999.
- 3) P. Krupp, P. Barnes. Clozapine-associated agranulocytosis risk and aetiology. *Br J Psychiatry*, 160, Suppl17, 38-40, 1992.
- 4) J. Munro, D. O’Sullivan, C. Andrews, A. Arana, A. Mortimer, R. Kerwin. Active monitoring of 12760 clozapine recipients in the UK and Ireland. *Br J Psychiatry*, 175, 576-580, 1999.
- 5) GL. Deliliers. Blood dyscrasias in clozapine-treated patients in Italy. *Haematologica*; 85, 233-237, 2000.
- 6) DL. Copolov, WR. Bell, WJ. Benson, NA. Keks, DC. Strazzeri, GF. Johnson. Clozapine treatment in Australia: a review of haematological monitoring. *Med J Aust*; 168, 495-497, 1998.
- 7) HS. Cho, CH. Kim, HS. Lee. Agranulocytosis and neutropenia in clozapine-treated patients with schizophrenia in Korea. *Schizophr Res*; 36, 274-275, 1999.

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

	Novartis <sup>a)</sup>	Novartis	Novartis (%)
Novartis	77	2	2.60
Novartis	77	6	7.79
Novartis	77	2	2.60

a) Novartis 1301, 1201, 1202, 1203

Novartis Pharmaceuticals Corporation





Table with 10 columns: Treatment, n, n (%), n (%).

Table with 10 columns: Treatment, n, n (%), n (%).

	n	n (%) <sup>a)</sup>							
Group 1	1,600	785 [49.1]	30 [1.9]	169 [10.6]	87 [5.4]	2 [0.1]	95 [5.9]	372 [23.2]	60 [3.8]
Group 2	4,261	1,974 [46.3]	43 [1.0]	413 [9.7]	214 [5.0]	7 [0.1]	199 [4.7]	1,386 [32.5]	25 [0.6]
Group 3 <sup>b)</sup>	2,490	945 [38.0]	45 [1.8]	298 [12.0]	198 [8.0]	2 [<0.1]	100 [4.0]	848 [34.1]	54 [2.2]

a) ... b) ...

...

...

...

<mailto:clozaril.remote@novartis.com>

0800-222-8814

9001730

...

0120-003-293

9001730

...

Source URL: https://www.loadtest.pro.novartis.com/products/clozaril/clinical/10